Skip to main content

Market Overview

Foxconn's Huawei Unit Workers Are Cashing Bigger Paychecks Than iPhone Assemblers

Share:
Foxconn's Huawei Unit Workers Are Cashing Bigger Paychecks Than iPhone Assemblers

In a surprising twist, Foxconn Technology Group has reportedly been offering its workers at the Huawei Technologies handset production unit higher wages than their counterparts in iPhone manufacturing, according to the South China Morning Post.

What Happened

The report states that Foxconn’s FIH unit oversees Huawei smartphone production and has been offering new workers in Shenzhen’s Longhua district an hourly rate of 26 yuan (US$3.60). In contrast, Foxconn’s iPhone-manufacturing unit, the Integrated Digital Product Business Group (iDPBG), offers a rate of 21 yuan (US$2.88).

This wage increase coincides with both Apple Inc (NASDAQ:AAPL) and Huawei’s recent launch of new 5G handsets in China, the world’s largest smartphone market. Even though iPhone 15 production commenced at Foxconn’s Indian factory last month, most of the iPhone 15 series will still be produced in China.

See Also: If You Invested In Apple Stock Instead Of Buying iPhones Each Year, Here’s How Much You’d Have Today

Why It Matters

Apple’s strategy to decentralize its supply chain from China and invest heavily in India’s production was reported earlier. The move was seen as a response to the COVID-19 outbreak and subsequent riots at Apple’s largest Chinese factory. Apple aims to manufacture 15 million iPhone 15 units in India this year.

However, despite these efforts, iPhone 15 prices in China, Japan, and India were higher than many other countries, despite local manufacturing and assembly.

Moreover, Apple’s latest smartphone lineup has seen differing consumer demand trends. According to analyst Ming-Chi Kuo, the iPhone 15 Pro faces decreased demand, while the Pro Max model shows remarkable sales performance. This shift in demand might have contributed to the wage discrepancy between the Huawei and iPhone production units at Foxconn.

Photo by duan zhi xiang

Read Next: Americans alone spend $100 billion on nicotine products per year. One startup has synthesized a medicine that eliminates the need to smoke in up to 95% of tested smokers. It's called Rexis Biotech and you can invest in it before the product's public release.


Engineered by
Benzinga Neuro, Edited by


Sudhanshu Singh


The GPT-4-based Benzinga Neuro content generation system exploits the
extensive Benzinga Ecosystem, including native data, APIs, and more to
create comprehensive and timely stories for you.
Learn more.


 

Related Articles (AAPL)

View Comments and Join the Discussion!

Posted-In: Appleverse Chinese Consumer Tech foxconn HuaweiNews Tech

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com